Patrik Vitazka

9.0k total citations · 1 hit paper
14 papers, 1.2k citations indexed

About

Patrik Vitazka is a scholar working on Genetics, Cancer Research and Molecular Biology. According to data from OpenAlex, Patrik Vitazka has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Cancer Research and 4 papers in Molecular Biology. Recurrent topics in Patrik Vitazka's work include Cancer Genomics and Diagnostics (5 papers), Genomics and Rare Diseases (4 papers) and RNA modifications and cancer (3 papers). Patrik Vitazka is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Genomics and Rare Diseases (4 papers) and RNA modifications and cancer (3 papers). Patrik Vitazka collaborates with scholars based in United States, Qatar and Germany. Patrik Vitazka's co-authors include Joseph D. Szustakowski, Giovanni Selvaggi, Fred R. Hirsch, Margaret K. Callahan, Ryan Golhar, Chang Han, Mark M. Awad, Matthew D. Hellmann, Ariella Sasson and Naiyer A. Rizvi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Molecular Biology.

In The Last Decade

Patrik Vitazka

13 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

2018 670 citations Matthew D. Hellmann, Margaret K. Callahan et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrik Vitazka United States	9	636	399	243	217	213	14	1.2k
Iván Plaza-Menacho United Kingdom	20	490 0.8×	598 1.5×	241 1.0×	248 1.1×	142 0.7×	27	1.3k
Lorena Bottarelli Italy	18	661 1.0×	454 1.1×	367 1.5×	67 0.3×	218 1.0×	51	1.1k
Synnöve Staff Finland	20	429 0.7×	454 1.1×	79 0.3×	158 0.7×	63 0.3×	48	1.2k
Marco Johannes Battista Germany	18	426 0.7×	245 0.6×	154 0.6×	44 0.2×	90 0.4×	76	998
François P. Duhoux Belgium	18	589 0.9×	318 0.8×	202 0.8×	91 0.4×	42 0.2×	92	1.2k
Andreas Doll Spain	20	296 0.5×	714 1.8×	314 1.3×	130 0.6×	47 0.2×	37	1.3k
Hector Arango United States	10	329 0.5×	455 1.1×	101 0.4×	373 1.7×	196 0.9×	15	1.2k
Inko Nimmrich Germany	18	329 0.5×	725 1.8×	221 0.9×	168 0.8×	68 0.3×	24	1.1k
Eva Colás Spain	21	231 0.4×	624 1.6×	185 0.8×	103 0.5×	56 0.3×	42	1.2k
Vasily N. Aushev United States	16	397 0.6×	726 1.8×	127 0.5×	80 0.4×	97 0.5×	59	1.1k

Countries citing papers authored by Patrik Vitazka

Since Specialization

Citations

This map shows the geographic impact of Patrik Vitazka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrik Vitazka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrik Vitazka more than expected).

Fields of papers citing papers by Patrik Vitazka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrik Vitazka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrik Vitazka. The network helps show where Patrik Vitazka may publish in the future.

Co-authorship network of co-authors of Patrik Vitazka

This figure shows the co-authorship network connecting the top 25 collaborators of Patrik Vitazka. A scholar is included among the top collaborators of Patrik Vitazka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrik Vitazka. Patrik Vitazka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Prat, Aleix, Shanu Modi, Junji Tsurutani, et al.. (2023). Abstract HER2-18: HER2-18 Determination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04. Cancer Research. 83(5_Supplement). HER2–18. 5 indexed citations

Lovejoy, Alexander F., Hai Lin, David M. Kurtz, et al.. (2019). Changes in circulating tumor DNA levels are associated with treatment response and progression-free survival in relapse/refractory DLBCL subjects.. Journal of Clinical Oncology. 37(15_suppl). 7546–7546. 1 indexed citations

Qi, Zhenhao, Lisu Wang, Keyur Desai, et al.. (2019). Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin–Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform. Journal of Molecular Diagnostics. 21(5). 796–807. 17 indexed citations

Lovejoy, Alexander F., Hai Lin, Christopher R. Bolen, et al.. (2019). Molecular Characteristics and Disease Burden Metrics Determined By Next-Generation Sequencing on Circulating Tumor DNA Correlate with Progression Free Survival in Previously Untreated Diffuse Large B-Cell Lymphoma. Blood. 134(Supplement_1). 490–490. 4 indexed citations

Hellmann, Matthew D., Margaret K. Callahan, Mark M. Awad, et al.. (2018). Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 33(5). 853–861.e4. 670 indexed citations breakdown →

Yaung, Stephanie J., Xi Liu, Bernd Hinzmann, et al.. (2018). Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.. Journal of Clinical Oncology. 36(15_suppl). 12045–12045.

Millan, Francisca, Megan T. Cho, Kyle Retterer, et al.. (2016). Whole exome sequencing reveals de novo pathogenic variants in KAT6A as a cause of a neurodevelopmental disorder. American Journal of Medical Genetics Part A. 170(7). 1791–1798. 42 indexed citations

Al‐Dewik, Nader, Mariam Al‐Mureikhi, Rehab Ali, et al.. (2015). High diagnostic yield of clinical exome sequencing in Middle Eastern patients with Mendelian disorders. Human Genetics. 134(9). 967–980. 140 indexed citations

Hegde, Madhuri, Sherri J. Bale, Pınar Bayrak‐Toydemir, et al.. (2015). Reporting Incidental Findings in Genomic Scale Clinical Sequencing—A Clinical Laboratory Perspective. Journal of Molecular Diagnostics. 17(2). 107–117. 44 indexed citations

10.

Ye, Yizhou, Megan T. Cho, Kyle Retterer, et al.. (2015). De novo POGZ mutations are associated with neurodevelopmental disorders and microcephaly. Molecular Case Studies. 1(1). a000455–a000455. 39 indexed citations

11.

Shang, Linshan, Megan T. Cho, Kyle Retterer, et al.. (2015). Mutations in ARID2 are associated with intellectual disabilities. Neurogenetics. 16(4). 307–314. 43 indexed citations

12.

Lyon, Elaine, Glenn E. Palomaki, Victoria M. Pratt, et al.. (2012). Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genetics in Medicine. 14(12). 990–1000. 34 indexed citations

13.

Sandhu, Bimaljit S., Patrik Vitazka, Andrea Ferreira‐Gonzalez, et al.. (2011). Presence of SPINK‐1 variant alters the course of chronic pancreatitis. Journal of Gastroenterology and Hepatology. 26(6). 965–969. 8 indexed citations

14.

Elkins, P.A., Joseph Watts, Magdalena Zalacaín, et al.. (2003). Insights into Catalysis by a Knotted TrmD tRNA Methyltransferase. Journal of Molecular Biology. 333(5). 931–949. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact